Skip to main content

Table 1 Baseline characteristics of study cases with febuxostat and allopurinol

From: Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study

Characteristics

Acute renal failure with febuxostat as the suspected drug (n = 317)

Acute renal failure with allopurinol as the suspected drug (n = 1008)

Age, years, mean (SD)

68.0 (15.0)

67.0 (14.5)

Age, n (%)

 19–44

27 (8.5)

79 (7.8)

 45–64

83 (26.2)

306 (30.4)

 65–74

81 (25.6)

270 (26.8)

 ≥ 75

126 (39.7)

353 (35.0)

Sex, n (%)

 Male

172 (54.3)

577 (57.2)

 Female

145 (45.7)

431 (42.8)

Reporter qualification, n (%)

 Healthcare professional

281 (88.6)

863 (85.6)

 Not a healthcare professional

17 (5.4)

41 (4.1)

 Unknown

19 (6.0)

104 (10.3)

 The only suspected drug, n (%)

184 (58.0)

447 (44.3)

Continent, n (%)

 North America

115 (36.3)

233 (23.1)

 Europe

115 (36.3)

489 (48.5)

 Asia

82 (25.9)

237 (23.5)

 Other regions*

5 (1.6)

49 (4.9)

Seriousness of ARF

 Death

22 (6.9)

97 (9.6)

 Life-threatening event

32 (10.1)

111 (11.0)

 Disability/incapacity

18 (5.7)

13 (1.3)

 Hospitalization (caused or prolonged)

115 (36.3)

482 (47.8)

 Others

70 (22.1)

111 (11.0)

 Unknown

60 (18.9)

194 (19.2)

  1. *Included Oceania and Africa